Trial Profile
A phase II trial of GRT 6005 in patients with neuropathic and/or nociceptive pain
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2010
Price :
$35
*
At a glance
- Drugs Cebranopadol (Primary)
- Indications Neuropathic pain; Pain
- Focus Therapeutic Use
- Sponsors Forest Laboratories; Grunenthal
- 08 Dec 2010 New trial record